Results 251 to 260 of about 130,679 (320)
Medetomidine-vatinoxan-methadone and acepromazine-methadone: comparison of sedative and cardiovascular properties as a preanaesthetic medication in healthy dogs. [PDF]
Pekkola V +4 more
europepmc +1 more source
ABSTRACT Introduction A group of synthetic opioids, the nitazenes, is appearing in the illicit drug market. Monitoring these novel psychoactive substances is challenging due to constantly evolving analogues and the small amounts of these potent drugs that are consumed.
Emma L. Keller +6 more
wiley +1 more source
Behavioural Effects and Naloxone Effectiveness With New Synthetic Opioids
ABSTRACT Introduction The global drug market has seen an emergence of potent synthetic opioids, including benzimidazole‐derived substances known as nitazenes. These compounds have been implicated in fatal and non‐fatal overdoses. This review aims to synthesise current evidence on the pharmacological effects, potency and naloxone responsiveness of new ...
Suzanne Nielsen +8 more
wiley +1 more source
Intraoperative pain management for patients undergoing medication-assisted rehabilitation: a scoping review. [PDF]
Henriksen M, Ellingsen S, Kaldheim HKA.
europepmc +1 more source
Tell-Tale SNPs: The Role of CYP2B6 in Methadone Fatalities.
Taha Ahmad +4 more
semanticscholar +1 more source
ABSTRACT Issues From extracting insights from large‐scale, multimodal data to prevention and support, there is growing interest in the applications and implications of recent advances in Artificial Intelligence (AI) within the fields of addiction, substance use and mental health, which we refer to as ASUM.
Loïs Vanhée, Simone Scarpa
wiley +1 more source
Perioperative Methadone in Orthopedic Surgery: A Scoping Review. [PDF]
Yang AF, Lee E, Babaei M, Lee P.
europepmc +1 more source
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
H. Jones +9 more
semanticscholar +1 more source
Community Pharmacy‐Based Injectable Opioid Agonist Treatment: Findings From a Canadian Pilot Program
ABSTRACT Introduction Access to evidence‐based treatment for opioid use disorder remains limited, particularly for individuals who have not responded to oral opioid agonist treatment (OAT). A community pharmacy‐based model of injectable OAT (iOAT) was piloted in Vancouver, Canada from March 2017 to December 2018. This brief report describes the program
Tamara Mihic +7 more
wiley +1 more source

